Atomic AI

We’re excited to announce the close of our $35M Series A financing! Atomic AI is fusing artificial intelligence and structural biology to unlock RNA drug discovery, designing RNA-targeted and RNA-based medicines to treat undruggable diseases. We're extremely thankful to all of our investors, including those participating in our Series A - Playground Global, 8VC, Factory, Greylock, Not Boring, AME Cloud Ventures, and renowned angel investors including GitHub ex-CEO Nat Friedman, Doug Mohr, Curai CEO Neal Khosla, and UC Berkeley professor and Arc Institute Co-founder Patrick David Hsu. https://lnkd.in/ggR7KnNB #ai #drugdiscovery #ml #rna

Navigating loops and bulges that form in two and three dimensions, figuring out force fields and understanding the >100 different chemical modifications that can tune function and metabolism - these are just some of the challenges in RNA therapeutics. Vivien Marx does an excellent job laying out the complexity and explaining how Atomic AI's combination of machine-learning, data acquisition, and wet lab experimentation & validation aims to overcome these obstacles to create new treatments for a range of conditions. 📰 Read the Nature Biotechnology profile, featuring interviews with Atomic CEO Raphael Townshend, CSO Manjunath Ramarao, and Scientific Advisors Gene Yeo and Percy Carter: https://rdcu.be/dR1PP #RNA #RNAmedicines #RNAbiology #RNAtherapeutics #machinelearning #AI #structuralbiology #drugdiscovery Nature Portfolio

Today, August 1, is #WorldRNADay! But did you know that August 1st was chosen since AUG correlates with three of the nucleotides that make up RNA - adenine, uracil and guanine - the code necessary for making proteins!    This day is a great reminder of the critical importance of this molecule that is central to the biology of life. From coding proteins to mRNA vaccines to pioneering gene expression research, RNA is at the core of many scientific innovations.    At Atomic AI, we are harnessing RNA’s power to develop revolutionary medicines!   Learn more: https://lnkd.in/eTrdsXrw   #RNA #RNAmedicines #RNAbiology #RNAtherapeutics #machinelearning #AI #structuralbiology #drugdiscovery

AI may be a cool tool, but it's a tool nonetheless, and not a panacea that's going to solve every single problem under the sun. It works well in areas where there's a significant amount of data associated with it; not so much in areas where there is not. So, what does this mean in #pharma? Atomic AI founder and CEO Raphael Townshend recently spoke to PharmTech about how #AI and #machinelearning can be best leveraged in #drugdiscovery, and where there are still gaps. Additional datasets are needed to address these limitations and push progress forward into the #drugdevelopment stages as well. 📺 Watch the interview: https://lnkd.in/engBrRYf 🕵🏽♀️ Learn how Atomic AI is generating RNA structural datasets and integrating machine learning foundation models with large-scale, in-house experimental wet-lab biology: https://lnkd.in/eTrdsXrw

We had a great time yesterday at #BIO2024! Thanks to everyone who attended our discussion about #AI in #drugdiscovery, as well as moderator Ayman AlAbdallah and fellow panelists Lee Cronin and Thomas Miller.

A must-attend #BIO2024 panel for anyone interested in #AIDrugDiscovery: Atomic AI founder & CEO Raphael Townshend will join other leaders to discuss the use of intelligent data acquisition, analysis and application of machine learning and AI in chemistry and structural biology. 🧮 New Tools, New Times: Chemical and Structural AI for Drug Discovery 🗓️ Wednesday June 5 ⌚ 1:45 - 2:45 pm PT 📍 24BC 🔹Ayman AlAbdallah, MBA, Partner, Mubadala Capital 🔹Lee Cronin, PhD, Founder and Chief Executive Officer, Chemify Limited 🔹Raphael Townshend, PhD, Founder & CEO, Atomic AI 🔹Thomas Miller, CEO and co-founder, Iambic Therapeutics https://lnkd.in/eqaxWV-u #drugdiscovery #drugdelivery #innovation #drugdevelopment #machinelearning #AI #structuralbiology

We are thrilled to announce the addition of Amanda Garner to Atomic’s Scientific Advisory Board. With her extensive, well-recognized and respected background in #RNA research and medicinal chemistry, her insight will be an incredible asset as we continue to push the boundaries of #drugdiscovery, merging #AI with structural biology to develop novel, more effective RNA medicines. Please join us in welcoming Dr. Garner to the Atomic team! Read more here: rb.gy/tjjn86

Atomic AI founder and CEO Raphael Townshend participated in a discussion with Secretary of State Antony J. Blinken during a visit to the Bay Area earlier this week. During the visit, Secretary Blinken met with a panel of industry and policy experts to talk about the nation's biotech and biomanufacturing industries and how they could best contribute to a sustainable, safe and secure American bioeconomy. Raphael shared his insights into the potential of #AI and the need for "strategic data reserves" supported by sustained investment from both the public and private sectors. The Secretary also heard calls for more resilient, sustainable pharmaceutical supply chains, with minimal disruptions to critical drug supplies and equitable access to essential medicines for all. See more here: rb.gy/3utmii #biosecurity #bioeconomy #biomanufacturing #biotech #AI

We’re looking forward to participating in next week’s #AlignSummit24!

How can we use foundation models to accelerate RNA-targeted drug discovery? Those participating in the #DrugDiscoveryChemistry event in San Diego this week can hear more about the evolution of the Atomic’s platform and its growing applications from Atomic's Head of Machine Learning Stephan Eismann. Not attending? You can learn more here: https://lnkd.in/emwVPwab #AI #ML #machinelearning #RNA #structuralbiology #drugdiscovery #drugdevelopment